Why Niagen Bioscience, Inc.’s (NAGE) Stock Is Up 5.07%
As of Wednesday, August 19, Niagen Bioscience, Inc.’s NAGE share price has surged by 5.07%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
| SECTOR | INDUSTRY |
| Consumer Staples | Personal Care Products |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
Cynthia McLaughlin
Michael Rose
Jenna Brashear
Tudor Pop
Cynthia McLaughlin
| Share Statistics | NAGE | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $249.8 | $250.9 | 29% |
|
| Shares Out (Mil) | 82.5 | 27.3 | 58% |
|
| Institutional Ownership | 65.1% | 50.0% | 41% |
|
| Float (Mil) | 59.1 | 33.2 | 51% |
|
| Beta | 2.10 | 0.64 | 94% |
|
| Avg Daily Volume (000s) | 571 | 147 | 60% |
|
| Price Change (52-week) |
(67.3%) | 55.2% | 10% |
|
| Growth | NAGE | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 16.9% | 1.8% | 77% |
|
| Net Income (5yr) | 23.5% | (4.8%) | 78% |
|
| EPS (5yr) | 21.2% | 2.3% | 70 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | 59.5% | (14.9%) | 95% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 1 | 1 | 1 | |
| Current EPS | ($0.010) | $0.090 | $0.100 | |
| Month Ago EPS | $0.030 | $0.190 | $0.290 | |
| # Rev Up | 1 | 1 | 0 | |
| # Rev Down | 1 | 0 | 1 | |
| Three Months Ago EPS | $0.030 | $0.190 | $0.290 | |
| Year/Year Chg | (200.0%) | (55.0%) | 25.0% | |
| Financials | NAGE | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $129 | $417 | 28% |
|
| Net Income (TTM) (Mil) | $16 | ($5) | 48% |
|
| EPS (TTM) | $0.201 | ($0.100) | 47% |
|
| Operating Cash Flow (TTM) (Mil) | $6 | $16 | 36% |
|
| Net Cash Flow (TTM) (Mil) | $6 | $3 | 53% |
|
| Long-Term Debt (Q1) (Mil) | $1 | $43 | 18% |
|
| Enterprise Value (Q1) (Mil) | $172 | $302 | 25% |
|
| Valuation | NAGE | Industry Median |
Percentile (All Stocks) |
|
| P/B | 3.03 | 1.66 | 64% |
|
| P/E | 16.6 | 15.5 | 42% |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | 0.8 | 0.6 | 37% |
|
| Ratios | NAGE | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 64.2% | 64.2% | 76% |
|
| Net Margin | 12.4% | 1.2% | 68% |
|
| ROA | 16.1% | (1.5%) | 94% |
|
| ROE | 21.8% | 1.0% | 82% |
|
| Liabilities to Assets | 22.6% | 48.8% | 15% |
|
| F-Score | 5 | 4 | 50% |
|
Niagen Bioscience, Inc. did not pass any screens on 8/20/2026.
Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.
Ⓒ 2026 American Association of Individual Investors